Literature DB >> 26956190

Apparent mineralocorticoid excess.

John W Funder1.   

Abstract

Apparent mineralocorticoid excess is a syndrome reflecting the absent or impaired activity of the enzyme 11β-hydroxysteroid dehydrogenase Type 2. It may be mild when the mutant enzyme retains some activity, or severe when activity is absolutely or essentially absent. Diagnosis relies on a triad of hypertension, hypokalemia and suppressed plasma aldosterone levels, plus an abnormal urinary cortisol to cortisone ratio, either free steroid or metabolites. Treatment is symptomatic in the mild form - correction of hypertension and hypokalemia - but needs to be prompt, vigorous and sustained in the severe form, which usually presents in neonates/infancy. Elucidation of the pathogenesis of apparent mineralocorticoid excess is an example of 'reverse translation', in that it proved prismatic for the demonstration of the physiologic mechanisms underlying the selective activation of epithelial mineralocorticoid receptors by aldosterone. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  11βhydroxysteroid dehydrogenase type 2; Aldosterone; Cortisol; Mineralocorticoid receptors; Urinary steroid metabolites

Mesh:

Substances:

Year:  2016        PMID: 26956190     DOI: 10.1016/j.jsbmb.2016.03.010

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  14 in total

Review 1.  Potassium Homeostasis: The Knowns, the Unknowns, and the Health Benefits.

Authors:  Alicia A McDonough; Jang H Youn
Journal:  Physiology (Bethesda)       Date:  2017-03

Review 2.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

Review 3.  Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited.

Authors:  Alexandre A da Silva; Jussara M do Carmo; Xuan Li; Zhen Wang; Alan J Mouton; John E Hall
Journal:  Can J Cardiol       Date:  2020-02-12       Impact factor: 5.223

Review 4.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

5.  Monogenic forms of low-renin hypertension: clinical and molecular insights.

Authors:  Priyanka Khandelwal; Jaap Deinum
Journal:  Pediatr Nephrol       Date:  2021-08-20       Impact factor: 3.651

6.  Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess.

Authors:  Alejandra Tapia-Castillo; Cristian A Carvajal; Jorge A Pérez; Carlos E Fardella
Journal:  Endocrine       Date:  2022-06-08       Impact factor: 3.925

Review 7.  Gut feelings about bacterial steroid-17,20-desmolase.

Authors:  Lindsey K Ly; Heidi L Doden; Jason M Ridlon
Journal:  Mol Cell Endocrinol       Date:  2021-01-24       Impact factor: 4.102

Review 8.  Obesity, kidney dysfunction, and inflammation: interactions in hypertension.

Authors:  John E Hall; Alan J Mouton; Alexandre A da Silva; Ana C M Omoto; Zhen Wang; Xuan Li; Jussara M do Carmo
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

Review 9.  Is There a Role for Genomics in the Management of Hypertension?

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Tracy A Williams; Paolo Mulatero
Journal:  Int J Mol Sci       Date:  2017-05-26       Impact factor: 5.923

Review 10.  The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.